154 related articles for article (PubMed ID: 27389710)
1. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
[No Abstract] [Full Text] [Related]
2. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
3. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
4. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
5. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
[No Abstract] [Full Text] [Related]
6. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
7. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
9. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
[TBL] [Abstract][Full Text] [Related]
10. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
11. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
14. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
15. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
16. Horizontal melanonychia.
Salman A; Eser A; Kaygusuz Atagunduz I; Ergun T
Actas Dermosifiliogr; 2017 Jun; 108(5):469-470. PubMed ID: 27543192
[No Abstract] [Full Text] [Related]
17. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
Yun S; Vincelette ND; Abraham I
JAMA Oncol; 2016 Jun; 2(6):828-9. PubMed ID: 27281623
[No Abstract] [Full Text] [Related]
18. Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia.
Fozza C; Bonfigli S; Longu F; Pardini S; Dore F
Blood Cells Mol Dis; 2016 Jan; 56(1):37. PubMed ID: 26603721
[No Abstract] [Full Text] [Related]
19. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]